Key Points
- Ije Nwokori purchased small tranches of Dr. Martens stock on Nov 11, Dec 11 and Jan 13 (176, 197 and 192 shares) at GBX 85, GBX 76 and GBX 78 respectively, each transaction totaling about £150, signaling modest insider accumulation.
- DOCS opened at GBX 75.95, trading near its 50‑day MA (GBX 77.89) but below the 200‑day MA (GBX 83.45), with a 1‑year range of GBX 43.02–100.87 and a market cap of £734.1m; last quarter EPS was GBX (0.90) while P/E is 44.68 and PEG 6.40.
- Analysts are split (two Buy, two Hold) with a consensus rating of Moderate Buy and an average target price reported at GBX 6,000.
Dr. Martens plc (LON:DOCS - Get Free Report) insider Ije Nwokori acquired 192 shares of Dr. Martens stock in a transaction that occurred on Tuesday, January 13th. The shares were purchased at an average price of GBX 78 per share, for a total transaction of £149.76.
Ije Nwokori also recently made the following trade(s):
- On Thursday, December 11th, Ije Nwokori bought 197 shares of Dr. Martens stock. The shares were acquired at an average price of GBX 76 per share, with a total value of £149.72.
- On Tuesday, November 11th, Ije Nwokori bought 176 shares of Dr. Martens stock. The shares were acquired at an average cost of GBX 85 per share, for a total transaction of £149.60.
Dr. Martens Trading Up 0.5%
Dr. Martens stock opened at GBX 75.95 on Friday. The firm's 50-day moving average is GBX 77.89 and its 200-day moving average is GBX 83.45. The company has a debt-to-equity ratio of 127.27, a quick ratio of 1.13 and a current ratio of 2.85. Dr. Martens plc has a 1 year low of GBX 43.02 and a 1 year high of GBX 100.87. The company has a market cap of £734.10 million, a P/E ratio of 44.68, a PEG ratio of 6.40 and a beta of 0.11.
Dr. Martens (LON:DOCS - Get Free Report) last announced its quarterly earnings data on Thursday, November 20th. The company reported GBX (0.90) earnings per share for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. On average, equities analysts expect that Dr. Martens plc will post 2.5809394 earnings per share for the current year.
Analyst Upgrades and Downgrades
DOCS has been the subject of several recent research reports. Peel Hunt reaffirmed a "buy" rating on shares of Dr. Martens in a report on Thursday, November 20th. Berenberg Bank restated a "buy" rating on shares of Dr. Martens in a research report on Thursday, November 27th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Dr. Martens currently has a consensus rating of "Moderate Buy" and an average target price of GBX 6,000.
Get Our Latest Research Report on Dr. Martens
About Dr. Martens
(
Get Free Report)
Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.
The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
